Seer, Inc.

SEER

$1.94

-2.02%

2026-09-03 16:00:00 EDT-$0.04

Healthcare

Biotechnology

NASDAQ

Active Trading

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. ...

Recent News of SEER

Business Wire8/13/2026Neutral

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the Company's Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Board of Directors Dear Members of the Board of Directors (the “Board”), Bradley L. Radoff and Michael Torok (together with certain of their affiliat.

MarketBeat8/11/2026Neutral

Seer Q2 Earnings Call Highlights

Seer NASDAQ: SEER reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers.

Seeking Alpha8/11/2026Neutral

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

GlobeNewsWire8/11/2026Neutral

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June 30, 2026.

GlobeNewsWire8/3/2026Neutral

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA.

Seer, Inc.

Recent News of SEER

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Seer Q2 Earnings Call Highlights

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Seer Q2 Earnings Call Highlights

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

Seer Stockholders Vote to Re-Elect All Seven of Seer's Director Nominees at 2026 Annual Meeting

Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.

Radoff-JEC Group Urges Seer Stockholders to Vote “FOR” All Three of its Independent, Highly Qualified Nominees on the WHITE Proxy Card TODAY

Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc.

Seer Urges Stockholders to Vote “FOR” Seer's Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Special Committee of Seer's Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Radoff-JEC Group Announces ISS' Support of its Case for Change at Seer, Inc.

Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight

The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company's Blatant Rewriting of History

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm

Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer's Director Nominees

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm

The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.

The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.

Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential

Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics

The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change

The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening

The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Seer Files ITC Complaint Against Nanomics

The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026

Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

The Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.

Seer Q1 Earnings Call Highlights

Seer, Inc. (SEER) Q1 2026 Earnings Call Transcript

Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer Files Patent Infringement Lawsuit Against Nanomics

Supply Chain of SEER

Upstream

Downstream

Proxies

Recent News of SEER

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Seer Q2 Earnings Call Highlights

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Seer Q2 Earnings Call Highlights

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

Seer Stockholders Vote to Re-Elect All Seven of Seer's Director Nominees at 2026 Annual Meeting

Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.

Radoff-JEC Group Urges Seer Stockholders to Vote “FOR” All Three of its Independent, Highly Qualified Nominees on the WHITE Proxy Card TODAY

Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc.

Seer Urges Stockholders to Vote “FOR” Seer's Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Special Committee of Seer's Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Radoff-JEC Group Announces ISS' Support of its Case for Change at Seer, Inc.

Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight

The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company's Blatant Rewriting of History

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm